Scribe takes USD 25m in CIRM funding to push CRISPR CVD programs into clinic

Scribe Therapeutics [has received more than USD 25 million](https://www.businesswire.com/news/home/20260618696563/en/Scribe-Therapeutics-Awarded-More-Than-%2425-Million-From-CIRM-to-Accelerate-Additional-CRISPR-Based-Gene-Editing-Therapies-for-Cardiometabolic-Disease-Into-Clinical-Trials) from the California Institute for Regenerative Medicine (CIRM) to advance two preclinical CRISPR-based programs targeting elevated lipoprotein(a) and triglycerides toward clinical development, reflecting sustained state-level investment in in vivo gene editing for cardiovascular disease. The awards, made through CIRM's Preclinical Development Program, support STX-1200 and STX-1400, both built on Scribe's proprietary X-Editor (XE) platform. STX-1200 targets the LPA gene to durably reduce Lp(a) levels in patients with genetically elevated Lp(a), a condition affecting roughly one in five people globally for which no approved therapy currently exists. STX-1400 targets APOC3 to lower triglyceride-rich lipoproteins, addressing severe hypertriglyceridemia and familial chylomicronemia syndrome, where acute pancreatitis risk is substantial and current management options remain limited. Both programs are designed as single-dose interventions, a key differentiator from existing chronic-dosing lipid-lowering agents such as RNA interference therapies and PCSK9 inhibitors. Scribe's XE platform uses an engineered CasX enzyme with a staggered DNA cleavage mechanism, reported to achieve greater than 100-fold higher editing efficiency than naturally occurring CasX in cell-based assays. The platform's compact size supports in vivo delivery, which remains a central challenge for liver-targeted gene editing programs across the field. The cardiometabolic gene editing space is increasingly competitive. [Intellia Therapeutics](https://allsci.com/news/clinical-trials/full-phase-iii-data-reinforce-intellias-lead-in-race-to-first-in-vivo-crispr-approval/) and [Verve Therapeutics](https://allsci.com/news/clinical-trials/eli-lilly-posts-first-data-from-verve-acquired-in-vivo-base-editor-in-hypercholesterolemia-trial/) are advancing in vivo base editing and CRISPR approaches targeting PCSK9 and ANGPTL3, while Alnylam Pharmaceuticals has an approved RNA interference therapy for FCS. Scribe's differentiation rests on the XE platform's specificity profile and its wholly-owned pipeline, which also includes the clinical-stage [STX-1150](https://allsci.com/news/clinical-trials/scribes-epigenetic-silencer-targeting-pcsk9-for-single-dose-ldl-reduction-enters-first-human-trial/), a PCSK9-targeting epigenetic silencing asset partnered with Sanofi and Eli Lilly. The CIRM awards position Alameda, California-based [Scribe ](https://app.allsci.com/organization/ASC-OH-0000000004948-1.0-1772142984)to accelerate IND-enabling work on both programs. [Brett Staahl](https://app.allsci.com/researcher/ASC-PR-0000036707362-1.0-1722656023), Ph.D., co-founder and VP of External Innovation, is listed as principal investigator for STX-1200 and STX-1400. *** This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: [https://allsci.com/news/](https://allsci.com/news/) --- Spot something wrong? [Report an issue with this article](https://newsgen-prod.reframedata.com/feedback/crispr-gene-editing-cardiovascular-scribe)